Butabarbital
| Butabarbital | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 212.25 g/mol [1] |
| Appearance | Fine, white, microcrystalline powder [1] |
| Odor | Odorless [1] |
| Taste | Bitter [1] |
| Melting point | 166.5 °C [1] |
| Decomposition | When heated to decomp it emits toxic fumes of oxides of /nitric oxide/. [1] |
| Solubility | WHITE POWDER; PRACTICALLY INSOL IN BENZENE & ABS ETHER /SODIUM SALT/ [1] |
| Predicted LogP | 1.6 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C10H16N2O3 |
| IUPAC name | 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione |
| SMILES | CCC(C)C1(C(=O)NC(=O)NC1=O)CC |
| InChI | InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15) |
| InChIKey | ZRIHAIZYIMGOAB-UHFFFAOYSA-N |
| CAS number | 125-40-6 |
| UNII | P0078O25A9 |
| PubChem CID | 2479 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 100 hours[3] |
| Excretion | Urine[4] |
Butabarbital (also known as Secbutabarbital, Secbutobarbitone, Butatab, Butisol, Butabarbitone, Secbubarbital, Medarsed, Unicelles, Nilox or Butrate) is a substance of the barbiturate class.
Chemistry
Stereochemistry []
Butabarbital is a racemic mixture of the enantiomers (optical activity ( + / - )).
Druglikeness
Lipinski's rule of five
Butabarbital matches Lipinski's rule of five.Pharmacology
MeSH Classification
- hypnotics and sedatives (M0010885)
Mechanism of action []
Barbiturates like butabarbital potentiate GABA-A receptors and inhibit receptors for neuronal acetylcholine, and kainate. GABA-A receptors are predominantly on the post-synaptic membrane, and upon activation, open chloride channels to hyperpolarize the neuron and decreased firing rate. Potentiation of GABAergic neurons produces sedation. Inhibition of neuronal acetylcholine receptors and glutamate receptors of the kainate subtype desensitize their respective neurons, producing sedation. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| GABRA1 | shared target | 32 |
|---|---|---|
| GABRA2 | shared target | 32 |
| GABRA3 | shared target | 32 |
| GABRA4 | shared target | 32 |
| GABRA5 | shared target | 32 |
| GABRA6 | shared target | 32 |
| GABRB1 | shared target | 32 |
| GABRB2 | shared target | 32 |
| GABRB3 | shared target | 32 |
| GABRD | shared target | 32 |
| GABRE | shared target | 32 |
| GABRG1 | shared target | 32 |
| GABRG2 | shared target | 32 |
| GABRG3 | shared target | 32 |
| GABRP | shared target | 32 |
| GABRQ | shared target | 32 |
Medical side effects []
34 side effects listed on drug labels in SIDER 4.1 (butabarbital).
- Angioedema
- Anxiety
- Apnoea
- Ataxia
- Confusional state
- Feeling abnormal
- Constipation
- Dermatitis exfoliative
- Dizziness
- Syncope
- Dermatitis
- Rash
- Body temperature increased
- Hallucination
- Headache
- Hypersensitivity
- Hypotension
- Nausea
- Nervousness
- Tension
- Nightmare
- Shock
- Loss of consciousness
- Vomiting
- Agitation
- Hyperkinesia
- Depressed level of consciousness
- Hepatocellular injury
- Liver injury
- Bradycardia
- Somnolence
- Hypoxia
- Respiratory failure
- Hypoventilation
Indications
- Insomnia
Subjective effects []
| bonzi / Butabarbital [] | |
|---|---|
Legal status []
- Brazil: Butabarbital is a B1.[5]
- Canada: Butabarbital is a Schedule IV.
- United States: Butabarbital is a Schedule III under the "Controlled Substances Act".
- Germany: Butabarbital is a Anlage II under the "Betäubungsmittelgesetz (BtMG)".
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 2479, Butabarbital. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/2479
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Butabarbital. UNII: P0078O25A9. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/P0078O25A9
Butisol. RxList. http://www.rxlist.com/butisol-drug.html
Maynert EW, Losin L. The metabolism of butabarbital (butisol) in the dog. The Journal of Pharmacology and Experimental Therapeutics. November 1955; 115(3):275–82. PMID 13272177.
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 18:01:50 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 18:01:45 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 18:01:46 |
| gsrs | ok | 2026-11-20 18:01:46 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014382) | 2026-11-20 18:01:46 |
| kegg | ok | 2026-11-20 18:01:48 |
| pubchem | ok | 2026-11-20 18:01:44 |
| missing (no r/tripreports posts mention it) | 2026-11-20 18:01:45 | |
| sider | ok | 2026-11-20 18:01:46 |
| structure | ok | 2026-11-20 18:01:45 |
| wikipedia | ok | 2026-11-20 18:01:46 |